Tech Company Financing Transactions
Ventyx Biosciences Funding Round
Ventyx Biosciences, based in Encinitas, raised $114 million from venBio, Cormorant Asset Management and Farallon Capital Management.
Transaction Overview
Company Name
Announced On
3/10/2021
Transaction Type
Venture Equity
Amount
$114,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to clinical development of immunology programs and advance preclinical programs against novel drug targets with its prolific drug discovery engine.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
662 Encinitas Blvd. 250
Encinitas, CA 92024
USA
Encinitas, CA 92024
USA
Phone
Undisclosed
Website
Email Address
Overview
We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Raju Mohan
Chief Medical Officer
Dick Gregg
Chief Scientific Officer
John Nuss
Vice President
Kathy Ogilvie
VP - Bus. Development
Chris Krueger
Browse more venture capital transactions:
Prev: 3/10/2021: Demostack venture capital transaction
Next: 3/10/2021: Songclip venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs